NCT Number: NCT00369148
Combination of Glinides With Premixed Insulin
Combination therapy of glinides with premixed insulin provides better glycemic control than premixed insulin alone.
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Nippon Kokan Hospital, Kawasaki, Kanagawa, Japan
About this study
Type 2 diabetic patients undergoing twice daily injections of premixed insulin are administered glinides (10mg of mitiglinide or 90 mg of nateglinide) at lunchtime without changing their insulin regimen. Twelve weeks after administration of the glinides, they are discontinued. HbA1c levels at the start of glinide administration, 12 weeks after administration, and 12 weeks after discontinuation are measured.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Clinical diagnosis of type 2 diabetes
- Who undergoes twice daily injection of premixed insulin
- Whose HbA1c is more than 6.5% and less than 8.0%
Exclusion criteria
- Whose change of HbA1c is more than 1.0% during 12 weeks observational period
Treatment and study plan
Primary outcomes
-
glycohemoglobin
Secondary outcomes
-
anhydroglucitol
-
lipid profile
-
body weight
-
blood pressure
Sponsors and collaborators
Lead sponsor
Keio University
Other
Registry information
Official study title
Evaluation of Usefulness of Combination Therapy of Rapid Acting Insulin Secretagogue (Glinide) With Premixed Insulin in Type 2 Diabetes
Important dates
- Study start
- 2004
- Study completion
- 2006
- First posted
- Aug 29, 2006
- Registry last updated
- Aug 26, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes
NCT06989697
Cognitive Ability, General, Type 2 Diabets Mellitus
Seongnam-si, South Korea
View Trial Details